{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:04:06Z","timestamp":1785891846517,"version":"3.56.0"},"reference-count":60,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Antimicrobial resistance (AR) is a problem that threatens the search for adequate safe and effective antibiotic therapy against multi-resistant bacteria like methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE) and Clostridium difficile, among others. Daptomycin is the treatment of choice for some infections caused by Gram-positive bacteria, indicated most of the time in patients with special clinical conditions where its high pharmacokinetic variability (PK) does not allow adequate plasma concentrations to be reached. The objective of this review is to describe the data available about the type of therapeutic drug monitoring (TDM) method used and described so far in hospitalized patients with daptomycin and to describe its impact on therapeutic success, suppression of bacterial resistance, and control of side effects. The need to create worldwide strategies for the appropriate use of antibiotics is clear, and one of these is the performance of therapeutic drug monitoring (TDM). TDM helps to achieve a dose adjustment and obtain a favorable clinical outcome for patients by measuring plasma concentrations of an administered drug, making a rational interpretation guided by a predefined concentration range, and, thus, adjusting dosages individually.<\/jats:p>","DOI":"10.3390\/antibiotics10030263","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T05:03:15Z","timestamp":1614920595000},"page":"263","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Impact on Antibiotic Resistance, Therapeutic Success, and Control of Side Effects in Therapeutic Drug Monitoring (TDM) of Daptomycin: A Scoping Review"],"prefix":"10.3390","volume":"10","author":[{"given":"Carolina","family":"Osorio","sequence":"first","affiliation":[{"name":"Evidence-Based Therapeutics Group, Clinical Pharmacology, Universidad de La Sabana, Ch\u00eda 140013, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Garz\u00f3n","sequence":"additional","affiliation":[{"name":"Evidence-Based Therapeutics Group, Clinical Pharmacology, Universidad de La Sabana, Ch\u00eda 140013, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-5551","authenticated-orcid":false,"given":"Diego","family":"Jaimes","sequence":"additional","affiliation":[{"name":"Evidence-Based Therapeutics Group, Clinical Pharmacology, Universidad de La Sabana, Ch\u00eda 140013, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Silva","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of La Sabana, Ch\u00eda 140013, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0243-2299","authenticated-orcid":false,"given":"Rosa-Helena","family":"Bustos","sequence":"additional","affiliation":[{"name":"Evidence-Based Therapeutics Group, Clinical Pharmacology, Universidad de La Sabana, Ch\u00eda 140013, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2020, January 13). WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. Available online: https:\/\/www.who.int\/es\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed."},{"key":"ref_2","unstructured":"World Health Organization (2021, January 15). Antimicrobial Resistance. Available online: https:\/\/www.who.int\/es\/news-room\/fact-sheets\/detail\/antimicrobial-resistance."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkx349","article-title":"Daptomycin","volume":"73","author":"Heidary","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_4","unstructured":"Tacconelli, E. (2017). Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Essential Medicines and Health Products, World Health Organization."},{"key":"ref_5","unstructured":"Centers for Disease Control and Prevention (CDC) (2021, January 15). Antibiotic\/Antimicrobial Resistance: Biggest Threats, Available online: http:\/\/www.cdc.gov\/drugresistance\/biggest_threats.html."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: A Position Paper","volume":"46","author":"Alffenaar","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1586\/17512433.2016.1172209","article-title":"Therapeutic drug monitoring of anti-infective agents in critically ill patients","volume":"9","author":"Jager","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/FTD.0b013e3181d3f5cb","article-title":"A Rapid High-Performance Liquid Chromatography Method to Measure Linezolid and Daptomycin Concentrations in Human Plasma","volume":"32","author":"Polillo","year":"2010","journal-title":"Ther. Drug Monit."},{"key":"ref_9","unstructured":"CDC (2021, January 15). Biggest Threats and Data, Available online: http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of Staphylococcus aureus bacteremia: A review","volume":"312","author":"Holland","year":"2014","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1016\/j.bmc.2016.05.052","article-title":"The action mechanism of daptomycin","volume":"24","author":"Taylor","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.7164\/antibiotics.41.1093","article-title":"Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: The synthesis and evaluation of daptomycin (LY146032)","volume":"41","author":"Debono","year":"1988","journal-title":"J. Antibiot."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.chembiol.2004.07.001","article-title":"Daptomycin structure and mechanism of action revealed","volume":"11","author":"Micklefield","year":"2004","journal-title":"Chem. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00249-007-0227-2","article-title":"Effect of divalent cations on the structure of the antibiotic daptomycin","volume":"37","author":"Ho","year":"2008","journal-title":"Eur. Biophys. J."},{"key":"ref_15","first-page":"29","article-title":"Daptomicina para el tratamiento de las infecciones por microorganismos grampositivos en el paciente cr\u00edtico","volume":"135","year":"2010","journal-title":"Med. Cl\u00edn."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1080\/10826076.2018.1492935","article-title":"An LC-MS\/MS method for quantification of daptomycin in dried blood spot: Application to a pharmacokinetics study in critically ill patients","volume":"41","author":"Cheng","year":"2018","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1093\/jac\/dkx140","article-title":"Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies","volume":"72","author":"Cojutti","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijantimicag.2018.09.015","article-title":"Current use of daptomycin and systematic therapeutic drug monitoring: Clinical experience in a tertiary care institution","volume":"53","author":"Galar","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10156-013-0559-z","article-title":"Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: Is therapeutic drug monitoring necessary?","volume":"19","author":"Falcone","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/FTD.0000000000000535","article-title":"Simple LC-MS\/MS Methods Using Core\u2013Shell Octadecylsilyl Microparticulate for the Quantitation of Total and Free Daptomycin in Human Plasma","volume":"40","author":"Miyadera","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s11096-019-00886-4","article-title":"Optimising antimicrobial therapy through the use of Bayesian dosing programs","volume":"41","author":"Avent","year":"2019","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/jac\/dkn414","article-title":"An HPLC assay for daptomycin in serum","volume":"62","author":"Tobin","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2125.2011.04080.x","article-title":"Therapeutic drug monitoring of antimicrobials","volume":"73","author":"Roberts","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.trac.2016.03.019","article-title":"The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine","volume":"84","author":"Decosterd","year":"2016","journal-title":"TrAC Trends Anal. Chem."},{"key":"ref_25","first-page":"1651","article-title":"New horizons to modern therapeutic drug monitoring\u2212use of tandem mass spectrometry to analyze the 40 most important anti-infectives","volume":"15","author":"Rodamer","year":"2009","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_26","first-page":"1624","article-title":"Therapeutic drug monitoring of daptomycin: A 4-year audit of levels from a UK clinical antibiotic service","volume":"18","author":"Sunderland","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/FTD.0000000000000740","article-title":"Real-Time Therapeutic Drug Monitoring-Based Pharmacokinetic\/Pharmacodynamic Optimization of Complex Antimicrobial Therapy in a Critically Ill Morbidly Obese Patient. Grand Round\/A Case Study","volume":"42","author":"Cojutti","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref_28","first-page":"e37","article-title":"TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient","volume":"45","author":"Pea","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3747\/pdi.2014.00271","article-title":"Successful Treatment of a Pacemaker Infection with Intraperitoneal Daptomycin","volume":"36","author":"Taegtmeyer","year":"2016","journal-title":"Perit. Dial. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1179\/joc.2011.23.4.238","article-title":"Daptomycin blood concentrations and clinical failure: Case report","volume":"23","author":"Tascini","year":"2011","journal-title":"J. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00216-009-3263-1","article-title":"Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma","volume":"396","author":"Baietto","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpba.2013.08.022","article-title":"Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots","volume":"88","author":"Baietto","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"122160","DOI":"10.1016\/j.jchromb.2020.122160","article-title":"Validation and clinical application of a multiplex high performance liquid chromatography\u2014tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections","volume":"1157","author":"Decosterd","year":"2020","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s00216-010-3639-2","article-title":"Daptomycin determination by liquid chromatography-mass spectrometry in peritoneal fluid, blood plasma, and urine of clinical patients receiving peritoneal dialysis treatment","volume":"397","author":"Gika","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpba.2015.10.008","article-title":"Simultaneous determination of ceftaroline, daptomycin, linezolid and rifampicin concentrations in human plasma by on-line solid phase extraction coupled to high-performance liquid chromatography-tandem mass spectrometry","volume":"118","author":"Gregoire","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpba.2018.05.015","article-title":"Liquid chromatography-tandem mass spectrometry for the quantification of moxifloxacin, ciprofloxacin, daptomycin, caspofungin, and isavuconazole in human plasma","volume":"157","author":"Hosl","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2012.12.028","article-title":"Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry","volume":"919\u2013920","author":"Jourdil","year":"2013","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"113132","DOI":"10.1016\/j.jpba.2020.113132","article-title":"A new validated HPLC-UV method for therapeutic monitoring of daptomycin in comparison with reference mass spectrometry","volume":"182","author":"Luci","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijid.2017.01.017","article-title":"Evaluation of pharmacokinetics and the stability of daptomycin in serum at various temperatures","volume":"57","author":"Ogami","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/FTD.0000000000000196","article-title":"Therapeutic Drug Monitoring of Daptomycin: A Retrospective Monocentric Analysis","volume":"37","author":"Reiber","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jpba.2018.11.047","article-title":"Development and validation of sensitive and selective quantification of total and free daptomycin in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry","volume":"165","author":"Tanaka","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.talanta.2013.07.043","article-title":"Simultaneous quantification of antimicrobial agents for multidrug-resistant bacterial infections in human plasma by ultra-high-pressure liquid chromatography-tandem mass spectrometry","volume":"116","author":"Tsai","year":"2013","journal-title":"Talanta"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jiac.2019.01.011","article-title":"Clinical pharmacokinetic and pharmacodynamic analysis of daptomycin and the necessity of high-dose regimen in Japanese adult patients","volume":"25","author":"Urakami","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1515\/CCLM.2011.005","article-title":"Determination of daptomycin in human plasma by liquid chromatography-tandem mass spectrometry. Clinical application","volume":"49","author":"Verdier","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jac\/dkr551","article-title":"Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration","volume":"67","author":"Wenisch","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.02000-12","article-title":"Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis","volume":"57","author":"Butterfield","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/FTD.0000000000000222","article-title":"Daptomycin: Physicochemical, Analytical, and Pharmacological Properties","volume":"37","author":"Garg","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wong, G., Sime, F.B., Lipman, J., and Roberts, J.A. (2014). How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-288"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/jcpt.13061","article-title":"Observational retrospective single-centre study in Japan to assess the clinical significance of serum daptomycin levels in creatinine phosphokinase elevation","volume":"45","author":"Ando","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2146\/ajhp110279","article-title":"Evaluation of a daptomycin dose-optimization protocol","volume":"69","author":"Tran","year":"2012","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/dkg130","article-title":"Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000\u20132001","volume":"51","author":"Critchley","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0213-005X(17)30028-9","article-title":"Actualizaci\u00f3n en la resistencia antibi\u00f3tica en Gram positivos","volume":"35","author":"Lozano","year":"2017","journal-title":"Enferm. Infecc. Microbiol. Cl\u00edn."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.3390\/molecules25122888","article-title":"Resistance of Gram-Positive Bacteria to Current Antibacterial Agents and Overcoming Approaches","volume":"25","author":"Karaman","year":"2020","journal-title":"Molecules"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: A review of its properties, function, and use in critical care","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1128\/AAC.06449-11","article-title":"High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis","volume":"56","author":"Entenza","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","first-page":"117","article-title":"Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment","volume":"74","author":"Marchand","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: Data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_60","unstructured":"The Joanna Briggs Institute (2015). Joanna Briggs Institute Reviewers\u2019 Manual: 2015 Edition\/Supplement, The Joanna Briggs Institute."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/3\/263\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:33:16Z","timestamp":1760160796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/3\/263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["antibiotics10030263"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10030263","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]}}}